Position in GRFS
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$552,990
+$55,855 QoQ
Shares Held
78,106
+26.0% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#54
of 164 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bleakley Financial Group, LLC holds $192,517,114 across 15 Drug Manufacturers - General names. GRFS ranks #14 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
45,004 | $53,979,152 | |
| 2 | JNJ |
Johnson & Johnson
|
142,327 | $36,146,788 | |
| 3 | ABBV |
AbbVie Inc.
|
92,109 | $23,178,308 | |
| 4 | MRK |
Merck & Co., Inc.
|
155,898 | $20,032,893 | |
| 5 | AMGN |
Amgen Inc
|
38,445 | $13,921,703 | |
| 6 | AZN |
Astrazeneca PLC
|
66,437 | $12,597,783 | |
| 7 | NVS |
Novartis AG
|
44,930 | $7,041,429 | |
| 8 | SNY |
Sanofi
|
159,361 | $6,798,340 |
All Filings in GRFS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $552,990 | 78,106 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $497,135 | 61,987 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $385,322 | 41,211 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $287,346 | 28,850 | Shares | Sole | 2025-11-10 | |
| No filing history on record for this holder in this stock. | ||||||